Key Highlights

● Immunovant surged on November 9 after IMVT-1402 met its primary endpoint.

● Over nine in ten patients on the higher dose reached ACR20 at Week 28.

● About three in four patients on placebo responded.

● Shares were up by a double-digit amount at 1:07 p.m. Eastern time.

The readout

Immunovant (NASDAQ:IMVT) surged on Monday, November 9, 2026, after the biotech company said a higher dose of its drug candidate IMVT-1402 met the primary endpoint in a rheumatoid arthritis trial. According to news reports, more than nine in ten patients on the higher dose achieved an ACR20 response at Week 28, compared with roughly three in four patients on placebo.

Live market data showed the shares up by a double-digit amount at 1:07 p.m. Eastern time, and other data captured a somewhat larger gain at points during the day.

What ACR20 measures

ACR20 is a standard yardstick in rheumatoid arthritis trials, developed by the American College of Rheumatology. A patient counts as an ACR20 responder if their counts of tender and swollen joints improve by at least a fifth, along with similar improvement in several other measures such as pain and physical function. It is a common primary endpoint because it captures whether a treatment is producing a meaningful benefit for patients.

The placebo group also posted a high response rate, so investors will want to see more detail on how the results compare with other treatments, including how patients fared on stricter measures of improvement and how quickly benefits appeared. But meeting the primary endpoint was the key hurdle, and the gap between the treatment and placebo groups was enough to win investors over on Monday.

How IMVT-1402 works

IMVT-1402 is an FcRn inhibitor. FcRn is a receptor that helps recycle a class of antibodies called IgG, extending their lifespan in the blood. In autoimmune diseases, some of those antibodies attack the body's own tissues. Blocking FcRn is designed to lower IgG levels, which could reduce the damage those harmful antibodies cause.

Because the mechanism is relevant to many autoimmune conditions, a positive result in one disease can raise investors' hopes for the broader program. Rheumatoid arthritis is a large market, which adds to the significance of a successful trial, and it is a field where doctors already have many options, so differentiation matters.

A biotech day full of contrasts

Immunovant was one of several drug developers making large moves on clinical data. Vir Biotechnology (NASDAQ:VIR) jumped after its Phase 3 ECLIPSE 1 trial in hepatitis Delta met its primary endpoint. Meanwhile, Zura Bio (NASDAQ:ZURA) collapsed after its tibulizumab failed its main goal in hidradenitis suppurativa, and Janux Therapeutics (NASDAQ:JANX) tumbled on disappointing early data.

The broader market was firmly in rally mode. The Nasdaq Composite climbed 673.71 points to 25,253.14, its best session since July 30, and the S&P 500 rose 173.08 points to 7,549.94. A powerful rebound in semiconductor stocks and a sharp slide in oil prices on hopes for a US-Iran peace deal powered the gains.

Next Steps After the Readout

Investors will look for Immunovant to present the full dataset from the rheumatoid arthritis trial, including safety findings, the lower-dose results and how durable the responses were. Those details will help determine how competitive IMVT-1402 could be in a crowded treatment landscape.

Next steps for the program, including plans for later-stage studies and readouts in other autoimmune diseases, will also be in focus. On the macro side, Tuesday's October Consumer Price Index is the last Inflation reading before the Federal Reserve's December 8-9 meeting, where a rate hike is widely expected, and interest-rate expectations can influence how investors value biotech companies with long development timelines.